Prognosis & Survival Rates for Invasive Lobular Breast Cancer: What You Need to Know

Regular follow‑up visits and diagnostic tests are crucial for early detection of recurrence or complications in patients treated for invasive lobular carcinoma (ILC). Your overall outlook depends on the cancer’s grade and stage, as well as the long‑term care strategy you and your oncology team develop.

The stage indicates tumor size and how far it has spread, while the grade reflects how abnormal the cancer cells appear and their potential to grow quickly. Pathologists determine these factors by examining biopsy samples under a microscope. Grading ranges from 1 (slow‑growing, least likely to spread) to 3 (rapid growth and dissemination). Knowing the grade helps guide treatment choices and provides a realistic prognosis.

Most ILC cases are hormone‑receptor positive—particularly estrogen‑positive—meaning the tumor requires estrogen to thrive. Antiestrogen therapies, such as selective estrogen receptor modulators or aromatase inhibitors, can reduce the risk of recurrence and improve survival.

Lobular vs. Ductal Breast Cancer Prognosis

ILC tumors can be larger and may spread more aggressively. On average, women diagnosed with ILC are about three years older than those with invasive ductal carcinoma (IDC) and are more frequently identified at an advanced stage. While long‑term outcomes for ILC are generally comparable to other invasive breast cancers, certain subgroups—particularly those with high‑grade tumors or inadequate initial treatment—experience poorer results.

Breast Cancer Survival Rates

Survival statistics are usually expressed as the percentage of patients alive five years after diagnosis, compared to the general population. They can also be reported at 10 years or beyond.

For localized disease (confined to the breast), the five‑year survival rate is approximately 99%. When cancer has involved regional lymph nodes, the rate drops to about 85%.

ILC Survival Rates

A 2021 analysis indicated that ILC patients enjoy a higher early‑stage survival but the rate tends to decline between 10 and 15 years post‑diagnosis. More recent data from 2024 report an overall five‑year survival of 88.6% and a ten‑year survival of 73.6% for ILC.

Because survival depends on many factors—tumor type, extent of spread, patient age, and treatment—the most reliable information comes from your own oncology team. Discuss your individual prognosis with them.

After completing treatment, schedule a physical exam and a mammogram every year. The first follow‑up should occur six months after surgery or radiation therapy finishes.

What Are the Symptoms of Invasive Lobular Carcinoma?

Unlike the classic lump, ILC may present as a thickening or hardening of the breast tissue, subtle swelling, changes in skin texture, dimpling, an inverted nipple, or localized pain in the breast or nipple.

Where Does Lobular Breast Cancer Spread?

ILC commonly metastasizes to regional lymph nodes and bones, but can also spread to distant organs such as the uterus, ovaries, stomach, brain, liver, and lungs.

What Is the Best Treatment for Lobular Carcinoma?

ILC’s diffuse growth pattern can make it difficult to detect on imaging, yet its slow‑growing nature gives clinicians time to plan a personalized approach. Standard care often includes lumpectomy followed by radiation, supplemented by systemic therapy—hormonal, targeted, or chemotherapy—based on receptor status and genetic profiling.

What Is the Most Aggressive Form of Breast Cancer?

While ILC is the second most common breast cancer type, it can occasionally be triple‑negative, lacking estrogen, progesterone, and HER2 receptors, which poses a higher risk of aggressive disease. Nonetheless, most ILC cases remain hormone‑receptor positive and are amenable to endocrine therapy.